Bayu Sisay on Muck Rack

Bayu Sisay

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Bayu

Contact Bayu, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

PRMT5 inhibition impairs Fanconi Anemia pathway-mediated homologous recombination and enhances the antitumor efficacy of Temozolomide in glioblastoma

|
By Shumpei Onishi, Sridharan Jayamohan, Ashis chowdhury, Sarah R. Rivas, Yoshihiro Otani, Celine Ertekin, Jean-Paul Bryant, Sara Murphy, Kimberly A. Rivera-Caraballo, Stuart Walbridge, Dragan Maric, Abdel G. Elkahloun, Kory R. Johnson, Desmond Brown Verified, John Heiss, Ashish Shah, Tae Jin Lee, Sangamesh G. Kumbar, Ji Young Yoo, Andrew Brenner, Balveen Kaur, Gangadhara R Sareddy, Bayu Sisay, Yeshavanth Kumar Banasavadi-Siddegowda
| Nature Verified
Abstract Despite multimodal therapy of surgical resection, radiation, and chemotherapy, glioblastoma patients show a dismal prognosis. Protein Arginine Methyltransferase 5 (PRMT5) is overexpressed in glioblastoma, and its inhibition imparts an anti-tumor effect. Tumor cells invariably develop resistance to Temozolomide (TMZ), the standard chemotherapeutic agent for glioblastoma. However, the mechanistic role of PRMT5 in treatment-resistant glioblastoma is unknown.
Open in Who Shared Issue with article?
See all 1 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified